Microvascular Therapeutics, Inc. (MVT), and SoundJet Medical, Inc. (SoundJet) announce that they have entered into a strategic collaboration to develop novel technology to treat vascular thrombosis. The technology is directed to more effectively treat deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT and PE affect almost 1 million people each year in the US and about 25% of patients with PE die from the disease.
Thom Tulip, PhD, Chief Business Officer of MVT said, “We are developing nanobubbles that, because of their tiny size, readily permeate the thrombus, and after activation with ultrasound, rapidly restores blood flow. We are looking forward to working closely with SoundJet because of their pioneering ultrasound Vortex technology.”
Chun-Yen Lai, PhD, Chief Executive Officer of SoundJet said, “We are very excited to work with MVT. We have optimized our ultrasound catheter system to maximize the benefit of MVT’s nanobubble technology. Together, MVT and SoundJet can provide a solution to the significant medical problems of DVT and PE.”
About MVT:
MVT is a biotechnology company based in Tucson, Arizona. MVT recently finished Phase II clinical trials of its new ultrasound contrast agent, MVT-100. MVT’s proprietary nanobubble technology derives from its ultrasound contrast agent technology which is late-stage development.
About SoundJet:
SoundJet is a medical device company incorporated in Delaware. The company has developed novel vortex technology that increases the activity of ultrasound for treatment of vascular thrombosis.
Company Contact:
Bryan Unger
T: 520.907.3537
Forward-Looking Statement:
This press release contains forward-looking statements that are based on current expectations as of the date of these statements. Results may differ substantially due to risks and uncertainties. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.
Comments